PolyPeptide Group Valuation
| PPGN Stock | CHF 24.20 0.15 0.62% |
At this time, the company appears to be overvalued. PolyPeptide Group holds a recent Real Value of ₣21.92 per share. The prevailing price of the company is ₣24.2. Our model determines the value of PolyPeptide Group from analyzing the company fundamentals such as Operating Margin of 0.15 %, shares outstanding of 33.12 M, and Return On Equity of 0.0809 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that PolyPeptide Group's price fluctuation is not too volatile at this time. Calculation of the real value of PolyPeptide Group is based on 3 months time horizon. Increasing PolyPeptide Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the PolyPeptide stock is determined by what a typical buyer is willing to pay for full or partial control of PolyPeptide Group AG. Since PolyPeptide Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PolyPeptide Stock. However, PolyPeptide Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.2 | Real 21.92 | Hype 24.35 | Naive 21.63 |
The intrinsic value of PolyPeptide Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PolyPeptide Group's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PolyPeptide Group AG helps investors to forecast how PolyPeptide stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PolyPeptide Group more accurately as focusing exclusively on PolyPeptide Group's fundamentals will not take into account other important factors: PolyPeptide Group Total Value Analysis
PolyPeptide Group AG is at this time anticipated to have takeover price of 755.81 M with market capitalization of 823.49 M, debt of 14.95 M, and cash on hands of 136.3 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the PolyPeptide Group fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
755.81 M | 823.49 M | 14.95 M | 136.3 M |
PolyPeptide Group Investor Information
About 60.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PolyPeptide Group last dividend was issued on the 28th of April 2022. Based on the analysis of PolyPeptide Group's profitability, liquidity, and operating efficiency, PolyPeptide Group AG is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.PolyPeptide Group Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PolyPeptide Group has an asset utilization ratio of 47.41 percent. This indicates that the Company is making ₣0.47 for each dollar of assets. An increasing asset utilization means that PolyPeptide Group AG is more efficient with each dollar of assets it utilizes for everyday operations.PolyPeptide Group Ownership Allocation
PolyPeptide Group owns a total of 33.12 Million outstanding shares. PolyPeptide Group has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.PolyPeptide Group Profitability Analysis
The company reported the revenue of 282.13 M. Net Income was 47.26 M with profit before overhead, payroll, taxes, and interest of 100.91 M.About PolyPeptide Group Valuation
Our relative valuation model uses a comparative analysis of PolyPeptide Group. We calculate exposure to PolyPeptide Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PolyPeptide Group's related companies.PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. The company was founded in 1952 and is headquartered in Zug, Switzerland. POLYPEPTIDE is traded on Switzerland Exchange in Switzerland.
8 Steps to conduct PolyPeptide Group's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates PolyPeptide Group's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct PolyPeptide Group's valuation analysis, follow these 8 steps:- Gather financial information: Obtain PolyPeptide Group's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine PolyPeptide Group's revenue streams: Identify PolyPeptide Group's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research PolyPeptide Group's industry and market trends, including the size of the market, growth rate, and competition.
- Establish PolyPeptide Group's growth potential: Evaluate PolyPeptide Group's management, business model, and growth potential.
- Determine PolyPeptide Group's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate PolyPeptide Group's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.